Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT06372444
Recruiting Observational

Mechanisms of Acute Kidney Injury in Severe Infections

NCT06372444 · tracked via the Priya Life Science Sweden tracker
Sponsor
Uppsala University Hospital
Phase
Observational
Started
2024-05-01
Last updated
2024-12-06

Condition(s) studied

SepsisAKI - Acute Kidney InjuryPositron Emission Tomography (PET)

Investigational drug(s) / intervention(s)

Positron emission tomography (PET)

Positron emission tomography (PET): Assessment of blood flow with marked water and assessment of neutrophil presence with neutrophil elastase tracer + CT

Study summary

Renal perfusion and neutrophil-mediated inflammation will be assessed in the kidney in sepsis patients with acute kidney injury using positron emission tomography. For marked water will be used for renal perfusion and a newly developed PET tracer molecule (11C-GW457427) with specific binding to neutrophil elastase which provides a measure of the amount of infiltrating neutrophils in the renal parenchyma for inflammation. The study is performed in a PET-CT camera where anatomical imaging takes place at the same time as the PET examinations.

Eligibility

Sex
ALL
Min age
30 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: Patients with sepsis and AKI * \> 30 years * At least AKI stage 1 according to KDIGO where the last plasma creatinine is measured within 24 hours of the examination Healthy volunteers * \> 30 years * No previously known kidney disease * Normal plasma creatinine value Exclusion Criteria: * Chronic renal failure (CKD stage \>3a) or dialysis * Instability in vital functions that makes PET-CT examination unsuitable * Claustrophobia or other reasons that make the patient unable to lie still during the examination. * Pregnancy and breastfeeding

Primary outcome measure(s)

  • Renal perfusion in patients with sepsis and acute kidney injury (AKI) measured by 15O-labeled water in dynamic positron emission tomography (PET) — PET performed within 10 days of AKI
    vs controls
  • Presence of neutrophil elastase in the kidneys in patients with sepsis and acute kidney injury (AKI) by 11C-GW457427 measured with dynamic positron emission tomography (PET) — PET performed within days of AKI
    vs controls

Trial sites (1)

FacilityCityRegionStatus
Uppsala university hospital Uppsala Sweden Recruiting

More Uppsala University Hospital trials in Sweden

Swedish National Parotidectomy Study (SNaPs): Drainless Versus Standard Surgery Recruiting
Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents Active, not recruiting
Postoperative Pain in Infants Starting soon
Fusion or no Fusion After Decompression of the Spinal Cord in Patients With Degenerative Cervical Myelopathy Recruiting
Clinical Investigation of Proton Treatment in Hodgkin Lymphoma Patients - PRO-Hodgkin Recruiting

Other trials for the same condition

Human Milk Fortification in Extremely Preterm Infants Active, not recruiting
Swecrit Biobank - Blood Samples From Critically Ill Patients and Healthy Controls Active, not recruiting
Bacteremia From Periodontal Treatment to Elucidate the Underpinnings of Sepsis Active, not recruiting
Post-Marketing Study to Assess the Safety & Efficacy of RenalGuard® Therapy for Prevention CSA-AKI Active, not recruiting
Establishment of Reference Limits for Blood Lactate Levels in Intensive Care Patients With a Particular Focus on Age and Sex Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06372444 on ClinicalTrials.gov ↗ ← All trials in Sweden